Malignant melanoma is a growing problem. In 1997 there will be in excess of 40,000 cases of malignant melanoma in the United States, with 7300 deaths occurring (1) . The incidence has been increasing by 5% per year for the last 40 years. Interestingly, the survival rate has also improved by almost 5 % per year (2) . The overall survival rate has gone from 60% to over 80% during this period. The prognostic variables that predict for a high likelihood of relapse among patients with primary cutaneous melanoma or regional lymph nodes recurrences are well established (3). Thus, there are well-defined groups of patients who can be targeted for biological therapy and gene therapy to prevent relapse. The immunological characteristics of malignant melanoma have been studied extensively and can be used to develop approaches to immunotherapy (4) . Tumor-associated or tumor-specific antigens have been described at the molecular level (5) . These can induce specific cytotoxic T cell (CTL) and antibody responses. This natural immune reactivity has provided the foundation for biological and gene therapy of melanoma. There is also abundant data that both general immunocompetence and specific immune reactivity to melanoma predict for a good prognosis (6) . Re- cently, molecular mechanisms have been described that explain how melanoma and other cancers evade the immune response and why anti-tumor host defense mechanisms fail. These provide additional targets for biological and gene therapy of melanoma.
TUMOR ANTIGENS IN MELANOMA
Tumor antigens have been studied intensively in malignant melanoma since the mid-1970s. Melanoma-associated antigens (MAA) were initially defined by reactivity of melanoma patients' sera against autologous and allogeneic melanoma cell lines. Through these studies, pioneered by Lloyd Old and co-workers, individual specific tumor antigens, common melanoma-associated antigens, and antigens cross-reactive with other tumors were recognized (7) (8) (9) . Subsequently, murine (10) and human ( 11) monoclonal antibodies were used to identify both cell membrane and cytoplasmic MAA. The development of CTL lines manifesting MHC class I-restricted cytotoxicity to autologous and allogeneic melanoma cells (12) led to the definition of a group of MAA, to the cloning of their genes, and to their use in active specific immunotherapy and gene therapy experiments (13) . MAA have been defined as lineage-specific, that is, they are limited to melanocytes and their precursors; to tumor progression antigens detected mainly in metastatic rather than primary melanomas, thus indicating a poor prognosis; and to T cell-recognized antigens, also referred to as cancer regression antigens (14) . Tyrosinase (15) , gp-75 (16) , high molecular weight MAA (HMW-MAA, gp-250, or chondroitin sulfate proteoglycan) (17) have been defined as lineage-specific. Progression antigens include MHC class II (HLA-DR) (18) , epidermal growth factor (EGF) receptor (19) , transferrin receptor (P97) (20) , the integrins a5f33 (21) , and Muc 18 (22) .
Since 1991 a growing number of MAA have been defined by cloning the genes for antigens recognized by CTL lines. This strategy, initially developed by Boon and colleagues (12) and ex-panded by Rosenberg and colleagues (23) , is important since these tumor rejection antigens can be exploited for biological and gene therapy. These antigens fall into several groups, including the MAGE, BAGE, and GAGE antigens, which are also found in other cancers (24, 25) ; tyrosinase (15, 16) , gp O00 (26), MelanA/MART-1 (27), and pMell7; and CDK4, MUM1, f3Catenin, GNT-V, and P1 5 (28). Another strategy to define MAA is to extract immunogeneic peptides from the MHC proteins of tumor lines, to characterize these by tandem mass spectroscopy and chromatography, and to test CTL reactive against T2 cells charged with the resultant peptides. This strategy has been carried out successfully (29) .
With this plethora of antigens, a variety of strategies for biological and gene therapy have been attempted (30). These include (1) active specific immunotherapy with antigen or immunogeneic peptide alone, with adjuvant, or as an immunoconjugate to a carrier protein; (2) immunization with plasmid DNA expressing the immunodominant peptide; (3) immunization with viral constructs expressing the peptide; (4) in vitro or in vivo-in vitro generation of CTL followed by in vitro expansion and adoptive immunotherapy; and (5) gene therapy with activated T cells transduced with the antigen-specific T cell receptor (TCR).
EVASION OF HOST CONTROL
Melanoma cells are poor antigen-presenting cells. The majority of primary melanomas express HLA class I antigens but about half of metastatic melanomas lose this antigen expression (31). In murine B 16 melanoma, tumor-infiltrating lymphocytes (TIL) isolated from class I-negative tumors do not lyse tumor cells and have no therapeutic activity compared with TIL from class I-positive tumors (32). Upregulation of class I by interferon y (IFN-,y) is a therapeutic strategy based on such findings (33) . Melanoma cells and other solid tumors fail to express the costimulatory molecule B7.1 which is necessary for effective antigen presentation and stimulation of CTL responses. Transfection of B7.1 into murine melanoma results in increased immunogenicity, loss of tumorigenicity, and resistance to subsequent rechallenge with wild-type tumor (34) . Interleukin 10 (IL-10) is a negative regulatory cytokine produced by a variety of cells (35) . It promotes TH2 cell activity and down-regulates the TH1 response necessary for the generation of CTL. Several human melanoma cell lines and fresh melanoma cell preparations express IL-10 mRNA and secrete IL-10 protein (36, 37) . Furthermore, elevated IL-10 levels have been identified in the blood of patients with metastatic melanoma (37) . Thus IL-10 is a possible target for IL-10 antibody, antisense, or ribozyme therapy. Many tumors also secrete transforming growth factor f3 (TGF-,B). It promotes angiogenesis and extracellular adhesion, and it inhibits mitogen and cytokine-induced T cell proliferation, the antibody response, and generation of cytotoxic lymphokine-activated killer (LAK) and CTL cells (38) . We (41) .
Tumors also evade host control by exploiting the fas system, a regulatory system for lymphocytes proliferation. CTL and natural killer (NK) cells use this as one mechanism of target cell killing (42) . Activated lymphocytes express fas ligand that interacts with fas on target cells and triggers apoptotic cell death. This is one of the three mechanisms for CTL killing, the others being release of perforins and granzymes (43) and TNF-a plus IFN-,y (44) . Tumor cells may also express fas ligand and its expression may be upregulated by chemotherapy (45) . Fas ligand expressing human melanoma cells has been shown to induce apoptosis in a fas-bearing lymphoma cell line (46) . Fas ligand has been found on human melanoma (47) , in hepatoma, and hepatic damage (45, 48) , on colon polyps (49) , and on colon cancer (50) . Stromal cells of the eye and sertoli cells of the testes also express high levels of fas ligand, which may explain these organs' immune privileged status (51) . Certain tumor antigens can also induce apoptoses in activated lymphocytes (DF3Mucl) (52) . Growth of fas ligand-positive murine melanoma is retarded in fas-deficient lpr mice, which suggests that when the invading CTL cannot be killed by the fas ligand-fas mechanism, effective CTL-mediated anti-tumor immunity is retained (53). Thus, the fas ligand system provides an attractive target for gene therapy of melanoma. Antibody antisense, or ribozymes directed to inactivate fas ligand, might all be effective in preventing killing of CTL by tumor cells.
A variety of mechanisms of host defense failure have been described in cancer patients. Recently in tumor-bearing mice and patients with a variety of malignancies, including cervical cancer, renal cancer, and melanoma, a structural abnormality in signal transducing zeta chains of CD3 and CD16 has been reported (54). This is associated with decreased lymphocyte cytokine response. Furthermore, survival in melanoma patients correlates with the level of TCR zeta chain (55). Impaired T cell function in cancer patients can also be overcome by IL-12. Longterm IL-2 treatment increases the number and activity of NK cells in cancer patients post-transplantation. Another possible mechanism is poor antigen presentation by dendritic cells. This has been described in breast cancer and can be overcome by culturing patient dendritic cell precursors in granulocyte macrophage-colony-stimulating factor (GM-CSF) (56 Anti-tumor immunity can also be overcome by increasing the dose of wild-type tumor cells on rechallenge. Thus, the tumor burden is a major factor in the by 1-to 5-fold efficacy of vaccine therapies.
Earlier work involving gene therapy of murine melanoma and other murine tumors has been summarized in a series of reviews published in 1994 and 1995 (65) (66) (67) (68) (69) (70) . More recent work is summarized below. This has tended to confirm and extend earlier observations without breaking much new ground. Almost all studies have been done in variants of B-16 melanoma, with emphasis on the highly metastatic clones. An important initial report by Dranoff et al. compared a spectrum of potential genes to augment tumor cell immunogenicity, including IL-2, -4, -5, and -6, INF-,y, ICAM-1, TNF-a, CD-2, and GM-CSF (71) . Animals were vaccinated with either nonirradiated or irradiated retrovirally transduced tumor cells and challenged at 7 to 17 days with wild-type cells. In both instances, major slowing of tumor growth was achieved only by GM-CSF-transduced cells, with slight effects noted for IL-4 and IL-6. Vaccination with viable irradiated GM-CSF-secreting cells can induce CTL in the draining lymph nodes and these can be expanded in vitro with IL-2. When administered at 7 X 107, cells together with systemic IL-2, they decreased pulmonary metastases after IV inoculation of wild-type cells (72) . Several studies have focused on the delivery of GM-CSF in Vaccinia virus constructs either by the intratumoral route (73) , vaccination with irradiated Vaccinia-infected cells (74) , or as a viral oncolysate (75) . In each study, a wild-type tumor was established 3 to 10 days prior to a single vaccination. Decreased tumor growth and number of metastases and increased survival was noted, which correlated with the generation of CTL and of activated cytotoxic macrophages producing TNF-a and nitrous oxide. The immunological effect was specific and there was no effect in these animals on transplanted colon tumors. Similar results have been described for tumor cells retrovirally transduced with the IL-2 gene (76) (107) . In a June 1997 update of melanoma gene therapy trials there were 11 cytokine immunotherapy trials for advanced cancer including melanoma, 19 cytokine immunotherapy trials specifically for melanoma, 3 lymphocyte transfer studies, and two HSV-TK/gancyclovir trials (108) . There were no clinical trials using drug-resistant genes or oncogenes, or tumorsuppressor gene modification. The TMC Development World-Wide Therapy Enrollment Report from December 1996 reported 37 melanoma trials involving 466 patients with 13 different genes (109) . Certainly, this level of effort should result in a substantial body of data within the next 2 years.
The first human cancer gene transfer trial reported by Rosenberg and co-workers utilized TIL cells from melanoma metastases expanded in vitro with IL-2, retrovirally transfected with the neo-R or TNF-a genes, and reinfused with systemic high-dose IL-2. Persistence of the transduced TIL was detected by polymerase chain reaction (PCR) in blood and tumor tissue (110) .
Five patients received up to 2 X 1011 marked cells (1-11% expressing the neo-R gene). There were no side effects and circulating cells were detected for up to 6 months. Three patients had regression of at least one tumor nodule, which is consistent with prior results for unmodified TIL therapy. The study was updated in 1993, reporting 10 patients with the same result (111). Additional similar studies have been reported (1 12 Autologous gene-modified fibroblasts have also been used to deliver cytokines intratumorally. In one study, retrovirally transformed autologous fibroblasts secreting 10 to 300 ng/ 106 cells/24 hr of IL-12 were given intratumorally weekly for four doses (120) . Three of seven melanoma patients showed partial remission. In another study, the autologous fibroblasts transduced to produce IL-4 were injected intratumorally ( 12 1 (124) . In a minority of patients, increased recognition of MAA by CTL precursors was observed. Viruses have also been used to directly transfer genes to tumors in vivo. One study showed that the Vaccinia E3L gene product was still expressed in tumors 2 months after intratumoral vaccination (125) . One of five patients had a local response. In another study, Vaccinia GM-CSF construct was injected intratumorally at 104 to 107 PFU twice weekly for 12 to 15 weeks (126) . One of three patients had a partial remission, including regression of noninjected metastases. A retroviral construct expressing the INF-,y gene has also been used by direct intratumoral injection in melanoma (127) . The dose was 1.5 X 108 CFU over 5 days into one nodule in three patients (127) . One showed successful gene transfer.
Another approach to melanoma gene therapy is the use of plasmid DNA complexed with the cationic lipid complex DMRIE/DOPE (128) . In the initial clinical study, five HLA-B7 negative patients were treated with multiple intratumoral injections of less than 1 mcg of HLA-B7 DNA complexed with DMRIE/DOPE (129) . Gene transfer and expression was documented in biopsies from of all five patients. Anti-tumor CTL developed in the two patients tested and 1/5 had a substantial partial remission. This group subsequently treated an additional 10 patients (130) . There was one local response in an injected nodule and one partial remission including uninjected metastases. The transferred gene was detected in 9 of 10 patients. Increased TIL were observed in six of seven postinjection biopsies. Specific CTL were obtained from tumor biopsies in 2 of 2 patients. Subsequent administration of in vitro-expanded CTL from the injected nodule of one of these biopsies induced a complete remission. These investigators also showed an increase in TCR-VB gene family diversity in both injected and noninjected lesions, which suggests that a systemic immune effect occurred after treatment (131) .
Our group initiated a formal phase I study of HLA-B7/f32M/DMRIE/DOPE intratumoral gene therapy in HLA-B7-negative, stage IV melanoma patients (132 (135, 136) . In another study, seven patients with metastatic malignant melanoma (three of whom were HLA-B7 positive but whose tumors did not express HLA-B7) were treated intratumorally with 10 mcg of HLA-B7 DNA in DMRIE/DOPE (137) . There were three responses, including two partial remissions, both in patients who were HLA-B7 positive. This suggests that restoration of HLA class I expression can induce anti-tumor immune responses. In these four phase I studies in melanoma a total of 36 patients were treated (138) . Thirty-six percent had a regression of the injected nodule and 19% had regression of disease at distant noninjected sites, which suggests the induction of generalized tumor immunity. Another group conducted a phase I study of 10, 20, or 50 mcg of HLA-B7 DNA in DMRIE/DOPE injected intratumorally every 2 weeks in patients who had a variety of malignancies including melanoma, head and neck cancer, and nonsmall-cell lung cancer (139) . One partial remission and one mixed response were noted in the two patients with lung cancer. HLA-B7, plasmid DNA complexed with DMRIE/DOPE was also delivered by the intra-arterial route to a lung nodule that expressed HLA-B7 DNA and protein (140) . On the basis of these data, phase II studies of HLA-B7 DNA intratumoral gene therapy are now being conducted in patients with different tumor types.
We have also conducted a phase I study of intratumoral injection plasmid DNA encoding the IL-2 gene complexed with DMRIE/DOPE in patients with various malignancies (141) on the basis of animal studies and data from our laboratory, showing efficient gene transfer to both fresh and cultured tumor cells. Doses of 10, 30, 100, and 300 mcg of DNA were given to cohorts of five to nine patients with metastatic malignancy weekly for six doses into the same nodule. DNA was detected in 75% of the patients, T 
